Mozart Therapeutics is developing first-in-class CD8 Treg modulators to restore immune homeostasis in patients with autoimmune diseases by targeting immune surveillance dysregulation. Their therapies aim to prevent progressive inflammation and tissue damage associated with pathogenic autoimmune responses.
Funding
$80M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autoimmune diseases are characterized by immune surveillance dysregulation, leading to progressive inflammation and tissue damage due to pathogenic autoimmune responses. Current treatments often manage symptoms but do not address the underlying cause of immune system dysfunction.
Solution
Mozart Therapeutics is developing first-in-class CD8 Treg modulators designed to restore immune homeostasis in patients with autoimmune diseases. These biologics target a fundamental cause of immune surveillance dysregulation, aiming to prevent progressive inflammation and tissue damage associated with pathogenic autoimmune responses. By modulating CD8 Treg dysfunction, Mozart's therapies seek to restore durable immune homeostasis across a range of autoimmune disorders. The company is advancing a pipeline of novel CD8 Treg modulators to address this unmet need.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and the healthcare providers who treat them.
Features
- First-in-class CD8 Treg modulators
- Designed to restore durable immune homeostasis
- Aims to avert progressive inflammation and tissue damage
- Targets a fundamental cause of immune surveillance dysregulation